Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 0.1236 USD 3% Market Closed
Market Cap: 17.8m USD

Applied Therapeutics Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Applied Therapeutics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Stock-Based Compensation
$13.9m
CAGR 3-Years
10%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$962m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$886m
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
$503m
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$696.1m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
$1B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
10%
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
17.8m USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
Not Available

See Also

What is Applied Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
13.9m USD

Based on the financial report for Sep 30, 2025, Applied Therapeutics Inc's Stock-Based Compensation amounts to 13.9m USD.

What is Applied Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
15%

Over the last year, the Stock-Based Compensation growth was 75%. The average annual Stock-Based Compensation growth rates for Applied Therapeutics Inc have been 10% over the past three years , 15% over the past five years .

Back to Top